NasdaqGS:ICLRLife Sciences
How Investors May Respond To ICON (ICLR) Surveying AI‑Driven R&D Resilience And Bottlenecks In Biotech
In early December 2025, ICON plc released findings from two extensive biotech sector surveys and a separate clinical trial site survey, revealing resilient global R&D activity, rising funding pressures, shifting therapeutic focus areas, and growing reliance on AI and digital technologies to streamline drug development.
The research highlights China’s increasing role in biotech innovation, alongside evidence that operational bottlenecks at trial sites and talent shortages in APAC are becoming...